{
    "id": "403e6073-a8f7-436f-9541-f39ec0a5a73e",
    "indications": "TYGACIL is a tetracycline class antibacterial indicated in patients 18 years of age and older for: • Complicated skin and skin structure infections ( 1.1 ) • Complicated intra-abdominal infections ( 1.2 ) • Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : TYGACIL is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia ( 1.4 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.5 ).",
    "contraindications": "• Initial dose of 100 mg followed by 50 mg every 12 hours administered intravenously over approximately 30 to 60 minutes. ( 2.1 ) • Severe hepatic impairment (Child Pugh C): Initial dose of 100 mg followed by 25 mg every 12 hours. ( 2.2 ) • Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with TYGACIL. ( 2.4 , 5.6 )",
    "warningsAndPrecautions": "TYGACIL (tigecycline) for injection is supplied in a single-dose 10 mL glass vial, containing 50 mg tigecycline lyophilized powder for reconstitution. \n                  Supplied:\n                  \n                     \n                     \n                     \n                        \n                           \n                              Unit of Sale\n                           \n                           \n                              Total Content\n                           \n                        \n                     \n                     \n                        \n                           \n                              \n                                 NDC 0008-4990-20\n                                 Box containing 10 single-dose vials\n                           \n                           \n                              50 mg/vial",
    "adverseReactions": "TYGACIL is contraindicated for use in patients who have known hypersensitivity to tigecycline or to any of the excipients. Reactions have included anaphylactic reactions [see Warnings and Precautions (5.3) and Adverse Reactions (6.2)].",
    "ingredients": [
        {
            "name": "TIGECYCLINE",
            "code": "70JE2N95KR"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        }
    ],
    "organization": "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",
    "name": "Tygacil",
    "effectiveTime": "20250429"
}